Liver Cancer - Pipeline Review, H2 2016

Date: December 30, 2016
Pages: 1171
Price:
US$ 2,500.00 US$ 2,000.00
Offer valid until June 2, 2017!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: LCA49CCACC6EN
Leaflet:

Download PDF Leaflet

Liver Cancer - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liver Cancer – Pipeline Review, H2 2016, provides an overview of the Liver Cancer (Oncology) pipeline landscape.

Liver cancer starts in the liver. The risk factors for liver cancer include hepatitis, cirrhosis, or scarring of liver, being male and having low weight at birth. Symptoms include a lump or pain on the right side of the abdomen and yellowing of the skin. Treatment of liver cancer may include chemotherapy, radiation and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Liver Cancer – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Liver Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Liver Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Liver Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 17, 76, 52, 8, 121 and 19 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 1, 15, 8, 1, 30 and 3 molecules, respectively.

Liver Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Liver Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Liver Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Liver Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Liver Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Liver Cancer (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Liver Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Liver Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Liver Cancer Overview
Therapeutics Development
Liver Cancer - Therapeutics under Development by Companies
Liver Cancer - Therapeutics under Investigation by Universities/Institutes
Liver Cancer - Pipeline Products Glance
Liver Cancer - Products under Development by Companies
Liver Cancer - Products under Investigation by Universities/Institutes
Liver Cancer - Companies Involved in Therapeutics Development
Liver Cancer - Therapeutics Assessment
Drug Profiles
Liver Cancer - Dormant Projects 1096
Liver Cancer - Discontinued Products 1116
Liver Cancer - Product Development Milestones 1120
Appendix 1133

LIST OF TABLES

Number of Products under Development for Liver Cancer, H2 2016
Number of Products under Development for Liver Cancer - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Development by Companies, H2 2016 (Contd..3)
Number of Products under Development by Companies, H2 2016 (Contd..4)
Number of Products under Development by Companies, H2 2016 (Contd..5)
Number of Products under Development by Companies, H2 2016 (Contd..6)
Number of Products under Development by Companies, H2 2016 (Contd..7)
Number of Products under Development by Companies, H2 2016 (Contd..8)
Number of Products under Development by Companies, H2 2016 (Contd..9)
Number of Products under Development by Companies, H2 2016 (Contd..10)
Number of Products under Development by Companies, H2 2016 (Contd..11)
Number of Products under Development by Companies, H2 2016 (Contd..12)
Number of Products under Development by Companies, H2 2016 (Contd..13)
Number of Products under Development by Companies, H2 2016 (Contd..14)
Number of Products under Investigation by Universities/Institutes, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Development by Companies, H2 2016 (Contd..4)
Products under Development by Companies, H2 2016 (Contd..5)
Products under Development by Companies, H2 2016 (Contd..6)
Products under Development by Companies, H2 2016 (Contd..7)
Products under Development by Companies, H2 2016 (Contd..8)
Products under Development by Companies, H2 2016 (Contd..9)
Products under Development by Companies, H2 2016 (Contd..10)
Products under Development by Companies, H2 2016 (Contd..11)
Products under Development by Companies, H2 2016 (Contd..12)
Products under Development by Companies, H2 2016 (Contd..13)
Products under Development by Companies, H2 2016 (Contd..14)
Products under Development by Companies, H2 2016 (Contd..15)
Products under Development by Companies, H2 2016 (Contd..16)
Products under Development by Companies, H2 2016 (Contd..17)
Products under Development by Companies, H2 2016 (Contd..18)
Products under Development by Companies, H2 2016 (Contd..19)
Products under Development by Companies, H2 2016 (Contd..20)
Products under Investigation by Universities/Institutes, H2 2016
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
Products under Investigation by Universities/Institutes, H2 2016 (Contd..3)
Liver Cancer - Pipeline by 4SC AG, H2 2016
Liver Cancer - Pipeline by AB Science SA, H2 2016
Liver Cancer - Pipeline by Acceleron Pharma Inc, H2 2016
Liver Cancer - Pipeline by ACROVIS Pharma AG, H2 2016
Liver Cancer - Pipeline by Adaptimmune Therapeutics Plc, H2 2016
Liver Cancer - Pipeline by Aduro BioTech Inc, H2 2016
Liver Cancer - Pipeline by Advenchen Laboratories LLC, H2 2016
Liver Cancer - Pipeline by Alfact Innovation, H2 2016
Liver Cancer - Pipeline by Alissa Pharma, H2 2016
Liver Cancer - Pipeline by Alnylam Pharmaceuticals Inc, H2 2016
Liver Cancer - Pipeline by American Gene Technologies International Inc, H2 2016
Liver Cancer - Pipeline by Amgen Inc, H2 2016
Liver Cancer - Pipeline by AndroScience Corp, H2 2016
Liver Cancer - Pipeline by APAvadis Biotechnologies Srl, H2 2016
Liver Cancer - Pipeline by ArQule Inc, H2 2016
Liver Cancer - Pipeline by Array BioPharma Inc, H2 2016
Liver Cancer - Pipeline by Astellas Pharma Inc, H2 2016
Liver Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2016
Liver Cancer - Pipeline by AstraZeneca Plc, H2 2016
Liver Cancer - Pipeline by AVEO Pharmaceuticals Inc, H2 2016
Liver Cancer - Pipeline by Bayer AG, H2 2016
Liver Cancer - Pipeline by BeiGene Ltd, H2 2016
Liver Cancer - Pipeline by Beijing Kawin Technology Share-Holding Co Ltd, H2 2016
Liver Cancer - Pipeline by Betta Pharmaceuticals Co Ltd, H2 2016
Liver Cancer - Pipeline by Bio-Cancer Treatment International Ltd, H2 2016
Liver Cancer - Pipeline by BioCancell Ltd, H2 2016
Liver Cancer - Pipeline by Biogazelle NV, H2 2016
Liver Cancer - Pipeline by Biomics Biotechnologies Co Ltd, H2 2016
Liver Cancer - Pipeline by Bioneer Corp, H2 2016
Liver Cancer - Pipeline by BioStar Pharmaceuticals Inc, H2 2016
Liver Cancer - Pipeline by BLR Bio LLC, H2 2016
Liver Cancer - Pipeline by Blueprint Medicines Corp, H2 2016
Liver Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016
Liver Cancer - Pipeline by Boryung Pharmaceutical Co Ltd, H2 2016
Liver Cancer - Pipeline by Boston Biomedical Inc, H2 2016
Liver Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2016
Liver Cancer - Pipeline by Can-Fite BioPharma Ltd, H2 2016
Liver Cancer - Pipeline by CASI Pharmaceuticals Inc, H2 2016
Liver Cancer - Pipeline by CBT Pharmaceuticals Inc, H2 2016
Liver Cancer - Pipeline by CCRP Therapeutics GmbH, H2 2016
Liver Cancer - Pipeline by Celgene Corp, H2 2016
Liver Cancer - Pipeline by Celldex Therapeutics Inc, H2 2016
Liver Cancer - Pipeline by Celprogen Inc, H2 2016
Liver Cancer - Pipeline by Celsion Corp, H2 2016
Liver Cancer - Pipeline by China Medical System Holdings Ltd, H2 2016
Liver Cancer - Pipeline by Chiome Bioscience Inc, H2 2016
Liver Cancer - Pipeline by Chipscreen Biosciences Ltd, H2 2016
Liver Cancer - Pipeline by Chroma Therapeutics Ltd, H2 2016
Liver Cancer - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2016
Liver Cancer - Pipeline by CohBar Inc, H2 2016
Liver Cancer - Pipeline by CZ BioMed Corp, H2 2016
Liver Cancer - Pipeline by Daiichi Sankyo Company Ltd, H2 2016
Liver Cancer - Pipeline by Delcath Systems Inc, H2 2016
Liver Cancer - Pipeline by Dicerna Pharmaceuticals Inc, H2 2016
Liver Cancer - Pipeline by Double Bond Pharmaceutical International AB, H2 2016
Liver Cancer - Pipeline by Eisai Co Ltd, H2 2016
Liver Cancer - Pipeline by Eli Lilly and Company, H2 2016
Liver Cancer - Pipeline by Endocyte Inc, H2 2016
Liver Cancer - Pipeline by Epeius Biotechnologies Corp, H2 2016
Liver Cancer - Pipeline by eTheRNA Immunotherapies NV, H2 2016
Liver Cancer - Pipeline by Eureka Therapeutics Inc, H2 2016
Liver Cancer - Pipeline by Exelixis Inc, H2 2016
Liver Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016
Liver Cancer - Pipeline by Faron Pharmaceuticals Oy, H2 2016
Liver Cancer - Pipeline by Formosa Laboratories Inc, H2 2016
Liver Cancer - Pipeline by Galaxy Biotech LLC, H2 2016
Liver Cancer - Pipeline by Genelux Corp, H2 2016
Liver Cancer - Pipeline by Genoscience Pharma, H2 2016
Liver Cancer - Pipeline by Genosco Inc, H2 2016
Liver Cancer - Pipeline by Gilead Sciences Inc, H2 2016
Liver Cancer - Pipeline by GlaxoSmithKline Plc, H2 2016
Liver Cancer - Pipeline by Golden Biotechnology Corp, H2 2016
Liver Cancer - Pipeline by Green Cross Cell Corp, H2 2016
Liver Cancer - Pipeline by Green Cross Corp, H2 2016
Liver Cancer - Pipeline by H3 Biomedicine Inc, H2 2016
Liver Cancer - Pipeline by HanAll Biopharma Co Ltd, H2 2016
Liver Cancer - Pipeline by HEC Pharm Co Ltd, H2 2016
Liver Cancer - Pipeline by HitGen LTD, H2 2016
Liver Cancer - Pipeline by Horizon Pharma Plc, H2 2016
Liver Cancer - Pipeline by Immune Therapeutics Inc, H2 2016
Liver Cancer - Pipeline by Immunicum AB, H2 2016
Liver Cancer - Pipeline by Immunitor Inc, H2 2016
Liver Cancer - Pipeline by Immunomedics Inc, H2 2016
Liver Cancer - Pipeline by Immunophotonics Inc, H2 2016
Liver Cancer - Pipeline by Immunovative Therapies Ltd, H2 2016
Liver Cancer - Pipeline by IMPACT Therapeutics Inc, H2 2016
Liver Cancer - Pipeline by In-Cell-Art SAS, H2 2016
Liver Cancer - Pipeline by Incanthera Ltd, H2 2016
Liver Cancer - Pipeline by Inovio Pharmaceuticals Inc, H2 2016
Liver Cancer - Pipeline by Inspyr Therapeutics Inc, H2 2016
Liver Cancer - Pipeline by InteRNA Technologies BV, H2 2016
Liver Cancer - Pipeline by Intezyne Technologies Inc, H2 2016
Liver Cancer - Pipeline by Jasco Pharmaceuticals LLC, H2 2016
Liver Cancer - Pipeline by Jenrin Discovery Inc, H2 2016
Liver Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2016
Liver Cancer - Pipeline by Johnson & Johnson, H2 2016
Liver Cancer - Pipeline by JW Pharmaceutical Corp, H2 2016
Liver Cancer - Pipeline by KAHR medical Ltd, H2 2016
Liver Cancer - Pipeline by Karcinolys SAS, H2 2016
Liver Cancer - Pipeline by Keystone Nano Inc, H2 2016
Liver Cancer - Pipeline by Kite Pharma Inc, H2 2016
Liver Cancer - Pipeline by Komipharm International Co Ltd, H2 2016
Liver Cancer - Pipeline by Kowa Company Ltd, H2 2016
Liver Cancer - Pipeline by Les Laboratoires Servier SAS, H2 2016
Liver Cancer - Pipeline by Lidds AB, H2 2016
Liver Cancer - Pipeline by Ligand Pharmaceuticals Inc, H2 2016
Liver Cancer - Pipeline by Lixte Biotechnology Holdings Inc, H2 2016
Liver Cancer - Pipeline by Lytix Biopharma AS, H2 2016
Liver Cancer - Pipeline by MaxCyte Inc, H2 2016
Liver Cancer - Pipeline by MedImmune LLC, H2 2016
Liver Cancer - Pipeline by Medivation Inc, H2 2016
Liver Cancer - Pipeline by Medivir AB, H2 2016
Liver Cancer - Pipeline by Merck & Co Inc, H2 2016
Liver Cancer - Pipeline by Merck KGaA, H2 2016
Liver Cancer - Pipeline by Merrimack Pharmaceuticals Inc, H2 2016
Liver Cancer - Pipeline by Midatech Pharma Plc, H2 2016
Liver Cancer - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
Liver Cancer - Pipeline by Mina Therapeutics Ltd, H2 2016
Liver Cancer - Pipeline by Molecular Partners AG, H2 2016
Liver Cancer - Pipeline by MultiCell Technologies Inc, H2 2016
Liver Cancer - Pipeline by NormOxys Inc, H2 2016
Liver Cancer - Pipeline by Northwest Biotherapeutics Inc, H2 2016
Liver Cancer - Pipeline by Novartis AG, H2 2016
Liver Cancer - Pipeline by NovaTarg Therapeutics Inc, H2 2016
Liver Cancer - Pipeline by Nymox Pharmaceutical Corp, H2 2016
Liver Cancer - Pipeline by Omeros Corp, H2 2016
Liver Cancer - Pipeline by Omnitura Therapeutics Inc, H2 2016
Liver Cancer - Pipeline by Oncolys BioPharma Inc, H2 2016
Liver Cancer - Pipeline by OncoMed Pharmaceuticals Inc, H2 2016
Liver Cancer - Pipeline by OncoTherapy Science Inc, H2 2016
Liver Cancer - Pipeline by Oneness Biotech Co Ltd, H2 2016
Liver Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016
Liver Cancer - Pipeline by Onxeo SA, H2 2016
Liver Cancer - Pipeline by OPKO Health Inc, H2 2016
Liver Cancer - Pipeline by Oribase Pharma, H2 2016
Liver Cancer - Pipeline by OSE Immunotherapeutics, H2 2016
Liver Cancer - Pipeline by Otsuka Holdings Co Ltd, H2 2016
Liver Cancer - Pipeline by Panacea Pharmaceuticals Inc, H2 2016
Liver Cancer - Pipeline by Peptinov SAS, H2 2016
Liver Cancer - Pipeline by PepVax Inc, H2 2016
Liver Cancer - Pipeline by Peregrine Pharmaceuticals Inc, H2 2016
Liver Cancer - Pipeline by Pfizer Inc, H2 2016
Liver Cancer - Pipeline by Pharma Mar SA, H2 2016
Liver Cancer - Pipeline by PharmAbcine Inc, H2 2016
Liver Cancer - Pipeline by PharmaEssentia Corp, H2 2016
Liver Cancer - Pipeline by Phosplatin Therapeutics LLC, H2 2016
Liver Cancer - Pipeline by ProMetic Life Sciences Inc, H2 2016
Liver Cancer - Pipeline by Provecs Medical GmbH, H2 2016
Liver Cancer - Pipeline by Provectus Biopharmaceuticals Inc, H2 2016
Liver Cancer - Pipeline by RedHill Biopharma Ltd, H2 2016
Liver Cancer - Pipeline by Regen BioPharma Inc, H2 2016
Liver Cancer - Pipeline by Regulus Therapeutics Inc, H2 2016
Liver Cancer - Pipeline by Rigontec GmbH, H2 2016
Liver Cancer - Pipeline by Samumed LLC, H2 2016
Liver Cancer - Pipeline by Saronic Biotechnology Inc, H2 2016
Liver Cancer - Pipeline by Savoy Pharmaceuticals Inc, H2 2016
Liver Cancer - Pipeline by Shenogen Pharma Group Ltd, H2 2016
Liver Cancer - Pipeline by Shenzen SiBiono GeneTech Co Ltd, H2 2016
Liver Cancer - Pipeline by Silence Therapeutics Plc, H2 2016
Liver Cancer - Pipeline by Sillajen Biotherapeutics, H2 2016
Liver Cancer - Pipeline by Simcere Pharmaceutical Group, H2 2016
Liver Cancer - Pipeline by Somantix BV, H2 2016
Liver Cancer - Pipeline by Sorrento Therapeutics Inc, H2 2016
Liver Cancer - Pipeline by Synovo GmbH, H2 2016
Liver Cancer - Pipeline by TaiRx Inc, H2 2016
Liver Cancer - Pipeline by Taiwan Liposome Company Ltd, H2 2016
Liver Cancer - Pipeline by Tara Immuno-Oncology Therapeutics LLC, H2 2016
Liver Cancer - Pipeline by Targetome SA, H2 2016
Liver Cancer - Pipeline by TC BioPharm Ltd, H2 2016
Liver Cancer - Pipeline by Tessa Therapeutics Pte Ltd, H2 2016
Liver Cancer - Pipeline by Therapure Biopharma Inc, H2 2016
Liver Cancer - Pipeline by Theravectys SA, H2 2016
Liver Cancer - Pipeline by Threshold Pharmaceuticals Inc, H2 2016
Liver Cancer - Pipeline by Tiziana Life Sciences Plc, H2 2016
Liver Cancer - Pipeline by TRACON Pharmaceuticals Inc, H2 2016
Liver Cancer - Pipeline by Transgene Biotek Ltd, H2 2016
Liver Cancer - Pipeline by Tumorend LLC, H2 2016
Liver Cancer - Pipeline by UbiVac LLC, H2 2016
Liver Cancer - Pipeline by VasGene Therapeutics Inc, H2 2016
Liver Cancer - Pipeline by Vaxon Biotech, H2 2016
Liver Cancer - Pipeline by Vect-Horus SAS, H2 2016
Liver Cancer - Pipeline by Verlyx Pharma Inc, H2 2016
Liver Cancer - Pipeline by VG Life Sciences Inc, H2 2016
Liver Cancer - Pipeline by Vicus Therapeutics LLC, H2 2016
Liver Cancer - Pipeline by Virttu Biologics Ltd, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Liver Cancer - Dormant Projects, H2 2016 1133
Liver Cancer - Dormant Projects (Contd..1), H2 2016 1134
Liver Cancer - Dormant Projects (Contd..2), H2 2016 1135
Liver Cancer - Dormant Projects (Contd..3), H2 2016 1136
Liver Cancer - Dormant Projects (Contd..4), H2 2016 1137
Liver Cancer - Dormant Projects (Contd..5), H2 2016 1138
Liver Cancer - Dormant Projects (Contd..6), H2 2016 1139
Liver Cancer - Dormant Projects (Contd..7), H2 2016 1140
Liver Cancer - Dormant Projects (Contd..8), H2 2016 1141
Liver Cancer - Dormant Projects (Contd..9), H2 2016 1142
Liver Cancer - Dormant Projects (Contd..10), H2 2016 1143
Liver Cancer - Dormant Projects (Contd..11), H2 2016 1144
Liver Cancer - Dormant Projects (Contd..12), H2 2016 1145
Liver Cancer - Dormant Projects (Contd..13), H2 2016 1146
Liver Cancer - Dormant Projects (Contd..14), H2 2016 1147
Liver Cancer - Dormant Projects (Contd..15), H2 2016 1148
Liver Cancer - Dormant Projects (Contd..16), H2 2016 1149
Liver Cancer - Dormant Projects (Contd..17), H2 2016 1150
Liver Cancer - Dormant Projects (Contd..18), H2 2016 1151
Liver Cancer - Dormant Projects (Contd..19), H2 2016 1152
Liver Cancer - Discontinued Products, H2 2016 1153
Liver Cancer - Discontinued Products (Contd..1), H2 2016 1154
Liver Cancer - Discontinued Products (Contd..2), H2 2016 1155
Liver Cancer - Discontinued Products (Contd..3), H2 2016 1156

LIST OF FIGURES

Number of Products under Development for Liver Cancer, H2 2016
Number of Products under Development for Liver Cancer - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Top 10 Routes of Administration, H2 2016
Number of Products by Stage and Top 10 Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016
Skip to top


Metastatic Liver Cancer - Pipeline Review, H2 2015 US$ 1,600.00 Oct, 2015 · 58 pages

Ask Your Question

Liver Cancer - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: